GlassScriptPhysician profile
Brian Gary Drage
NPI 1932278785
$2,988.18
in general payments reported to CMS, 2019-2025
30 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.32 · 2020: $138 · 2021: $1,290 · 2022: $406 · 2023: $259 · 2024: $346 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,216.53 | 2021 | |
| Abbvie INC. | $648.61 | 2022-2025 | Vraylar, Qulipta |
| Pfizer INC. | $132.71 | 2019-2025 | |
| Lilly USA, LLC | $103.61 | 2020-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $69.63 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $64.38 | 2022 | |
| Amgen INC. | $63.08 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $62.54 | 2020-2024 | Shingrix, Arexvy |
| Novo Nordisk INC | $55.14 | 2020-2025 | Rybelsus, Ozempic |
| Collegium Pharmaceutical, INC. | $52.26 | 2021-2025 | Belbuca |
| Boston Scientific Corporation | $49.78 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $46.12 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.18 | 2022-2023 | Synjardy, Jardiance |
| Vertex Pharmaceuticals Incorporated | $39.75 | 2025 | |
| Inspire Medical Systems, INC. | $37.61 | 2024-2025 | Inspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.62 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $29.21 | 2024-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $26.57 | 2021-2022 | |
| Axonics, INC. | $26.09 | 2020-2022 | |
| Impel Pharmaceuticals INC. | $24.56 | 2022 | |
| Abbott Laboratories | $21.05 | 2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $19.06 | 2024 | Veozah |
| Eisai INC. | $18.31 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2025 | Trintellix |
| Ultragenyx Pharmaceutical INC. | $15.76 | 2021 | |
| Coala Life INC | $15.58 | 2021 | |
| Collaborative Care Diagnostics, LLC | $14.58 | 2023 | |
| Medtronic, INC. | $13.91 | 2025 | Inceptiv |
| Exeltis, USA INC. | $13.61 | 2025 | Slynd |
| Qorumpartners | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Drage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.